Sanofi, Regeneron's Libtayo hits hot streak with EU green light, NICE backing

Libtayo bottle and box
Libtayo was the sixth player into the U.S. PD-1/PD-L1 market. (Sanofi Genzyme/Regeneron)

Sanofi and Regeneron’s Libtayo is two for two in the last two days—with European officials, that is. 

One day after the European Commission cleared the PD-1 drug to treat cutaneous squamous cell carcinoma, England’s cost watchdog signed off on an access agreement (PDF) for the product in adults whose disease can’t be treated with surgery or radiotherapy.

But it’s not an outright win for Libtayo at the National Institute for Health and Care Excellence (NICE). The cost-effectiveness gatekeeper will add the product to its Cancer Drugs Fund rather than cover it for routine use on the National Health Service.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

And as usual, the gatekeeper has some conditions. Patients should receive Libtayo until their disease progresses or they reach the two-year mark—whichever comes sooner, NICE said.

The reason? Libtayo’s trial data “are promising but uncertain,” NICE said in a final appraisal document (PDF). While it acknowledged that living with the disease is “physically and emotionally challenging” and “there is a high unmet need for new treatments,” the cost-effectiveness estimates for Libtayo “are above what is normally considered a cost-effective use of NHS resources” and it’s not clear how long the therapy prolongs life.

RELATED: Sixth-to-market Sanofi scores niche nod for PD-1 player—and blockbuster wannabe—Libtayo

NICE isn’t ruling out a jump to routine NHS use in the future, though. “If more mature data become available from an ongoing trial … and more data on life expectancy with current treatments are obtained,” Libtayo has the potential to eventually be considered a cost-effective treatment.

In England, Libtayo bears a list price of £4,650 per 350 mg vial, good for one treatment cycle. One year of Libtayo treatment rings up at £80,877. As is customary, though, NICE and Libtayo’s makers have struck a discount deal, though they’re keeping the details under wraps.

RELATED: Regeneron's Libtayo is chugging along in skin cancer. Next stop? First-line lung

NICE’s verdict is an important one, as countries around the world look to England to set the tone when it comes to drug reimbursement. And as of Monday, when the EC bestowed a go-ahead on the drug on the back of positive phase 2 data, European Union members will have their own negotiating to do.

The EU approval follows green lights in the U.S., Canada and Brazil. The FDA doled out its clearance last September, making Libtayo the sixth member in its class of immuno-oncology drugs to reach the market.

Right now, the Sanofi-Regeneron treatment is competition-free in the CSCC market, where it’s the only approved—I-O or otherwise. But the team is aiming to expand Libtayo into the lung cancer arena, where it’ll meet with fierce rivals from Merck, Roche and others.

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.